Autolus
Manufacturing · United Kingdom · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
191 Wood White City Ln, London, Greater ...Phone Number
+44 2038296230Website
www.autolus.comRevenue
$92.6 MillionStock Symbol
AUTLIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Autolus
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company headquartered in London, United Kingdom, founded in 2014. The company is focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus engineers precisely targeted, controlled, and highly active T cell therapies designed to better recognize target cells, break down their defense mechanisms, and eliminate them. The company's lead marketed therapy, AUCATZYL (obecabtagene autoleucel, obe-cel), is an FDA-approved CD19-directed CAR T cell therapy indicated for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, and has also received regulatory acceptance for review in Europe. Beyond its approved product, Autolus maintains a pipeline of product candidates in development across hematological malignancies, solid tumors, anRead more
Autolus Org Chart
Get the full picture
Sign in to uncover key details.
JS
Director, Revenue Accounting
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Autolus your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Autolus, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Autolus recently announced quarterly report
Click to see if Autolus had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Autolus has new funding data
Check out if Autolus is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Autolus launches new products
Check if Autolus has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Autolus
Recommended Actions
Find VP level buyers at Autolus
Find 3 more new buyers
Compare Similar Companies to Autolus
Compare insights from companies similar to Autolus, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$65.1M
501-1,000
Public
$485.9M
2008
MS
Mark StielowVice President, Manufacturing & Technical Operations (US)
Company Profile Activity
Activity Insights
Autolus is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Autolus is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Autolus.
Autolus financials insights
Gather financial insights about Autolus, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Series B
$54.3M
2021
Share Placement
$100M
Private Equity
$250M
Autolus Tech Stack
A closer look at the technologies used by Autolus
Most Recent Scoops
Open Position
Open Position
Project
Autolus has reported significant physician interest in exploring Obe-cel in the frontline B-ALL setting, with the rationale of replacing the current 18-to-36-month standard of care with a more compact consolidation approach to reduce cumulative toxicity and treatment-related mortality.
Doctors / Physicians, Pharmaceuticals
Earnings
Autolus has reported revenues of $74 million for fiscal year 2025, its first year of commercial launch, and has guided revenues of $128 million to $135 million for fiscal year 2026.
Earnings, Finance
Project
Pharmaceuticals, Clinical Operations
Autolus News & Media
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
Autolus announced preliminary second quarter 2026 AUCATZYL net product revenue that it has entered into a credit facility.Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On July 1, 2026, Autolus Therapeutics plc (NASDAQ:AUTL) announced that the Compensation Committee of its Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units to 13 employees […]Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus announced that the Compensation Committee of the Company's Board of Directors granted stock option awards.Autolus Therapeutics to Participate in Upcoming Investor Conference
Autolus will present at the H.C. Wainwright Cell Therapy Conference on June 30, 2026.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Autolus
Sign Up For FreeTo access detailed company insights
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company headquartered in London, United Kingdom, founded in 2014. The company is focused on developing, manufacturing, and delivering next-generation programmed T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell p... Read More
